June 2021

FDA Approves “First-in-Class” Nasal Antihistamine (Astepro Allergy) For OTC

Uncategorized

FDA Approves “First-in-Class” Nasal Antihistamine (Astepro Allergy) For OTC

Clark Richardson Participates in June 2021 FDA Public Workshop on the OTC Drug Facts Label

Uncategorized

Clark Richardson Participates in June 2021 FDA Public Workshop on the OTC Drug Facts Label

Address: 331 S Rio Grande St, Suite 100
Salt Lake City, UT 84101
Phone: (801) 487-9899
Email: info@pegus.com
Employment Opportunities: Visit this link

About Us

We are a unique, full-service OTC consumer behavior research organization. We specialize in the label comprehension, self-selection, and actual use studies that lead to successful OTC approval. We provide expert, end-to-end support for Drug Facts Label development and testing, including consulting, support for FDA interactions, protocol design, study conduct, site selection and management, monitoring, data management, statistics, medical writing and submission-ready data (CDISC) services.

Quick Links

Home

View our Website Privacy Policy, Study Privacy Notice and our Messaging Terms and Conditions

facebook
linkedin

Close Menu

Home
Services
Label Comprehension Studies
Self-Selection Studies
Actual Use Studies
International Consumer Behavior Studies

Address:
331 S Rio Grande St, Suite 100
Salt Lake City, UT 84101
Phone:
(801) 487-9899
Email:
info@pegus.com

facebook
linkedin

casibom giriş marsbahis giriş jojobet giriş Jojobet Casibom Giriş Jojobet Giriş Holiganbet Giriş